BX-1000 is under clinical development by and currently in Phase II for Anesthetic Effect. According to GlobalData, Phase II drugs for Anesthetic Effect have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BX-1000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BX-1000 overview
BX-1000 is under development for anaesthesia. The drug candidate is an intermediate-acting neuromuscular blocker. It is administered by intravenous bolus route.
Baudax Bio overview
develops and commercializes novel products for acute care settings that include product candidate meloxicam to treat osteoarthritis and rheumatoid arthritis. The company is headquartered in Chester, Pennsylvania, the US.
For a complete picture of BX-1000’s drug-specific PTSR and LoA scores,
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
